Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation

Mitchell E. Horwitz, Francesco Frassoni

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The outcome of umbilical cord blood transplantation for adult patients with hematologic malignancies now rivals that of matched unrelated donor transplantation. However, relatively low lymphocyte and hematopoietic stem and progenitor cell dose is a source of significant morbidity and mortality. Multiple strategies are now being studied to overcome these limitations. One strategy involves exvivo expansion of the umbilical cord blood unit before transplantation. Exvivo expansion has the potential to increase the number of lymphocytes, committed progenitors and long-term repopulating hematopoietic stem cells. Increasing the numbers of lymphocytes and committed progenitor cells will address the issue of delayed hematopoietic recovery after umbilical cord blood transplantation. Increasing the hematopoietic stem cell content will improve the availability of adequately sized and matched cord blood units for transplantation. It may also eliminate the need for dual umbilical cord blood transplantation for those without an adequately sized single umbilical cord blood graft. The second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Such a strategy may also address the problem of slow hematopoietic recovery as well as the increased risk of graft failure. Many of these strategies are now being tested in late-phase multi-center clinical trials. If proven cost-effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.

Original languageEnglish
Pages (from-to)730-738
Number of pages9
JournalCytotherapy
Volume17
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Fetal Blood
Transplantation
Transplants
Hematopoietic Stem Cells
Lymphocyte Count
Unrelated Donors
Stem Cell Transplantation
Hematologic Neoplasms
Stem Cells
Tissue Donors
Clinical Trials
Lymphocytes
Morbidity
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Oncology
  • Genetics(clinical)
  • Transplantation
  • Cancer Research
  • Cell Biology

Cite this

Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. / Horwitz, Mitchell E.; Frassoni, Francesco.

In: Cytotherapy, Vol. 17, No. 6, 01.06.2015, p. 730-738.

Research output: Contribution to journalArticle

@article{dc34d2a0e6474fd5babe78b4bcd31127,
title = "Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation",
abstract = "The outcome of umbilical cord blood transplantation for adult patients with hematologic malignancies now rivals that of matched unrelated donor transplantation. However, relatively low lymphocyte and hematopoietic stem and progenitor cell dose is a source of significant morbidity and mortality. Multiple strategies are now being studied to overcome these limitations. One strategy involves exvivo expansion of the umbilical cord blood unit before transplantation. Exvivo expansion has the potential to increase the number of lymphocytes, committed progenitors and long-term repopulating hematopoietic stem cells. Increasing the numbers of lymphocytes and committed progenitor cells will address the issue of delayed hematopoietic recovery after umbilical cord blood transplantation. Increasing the hematopoietic stem cell content will improve the availability of adequately sized and matched cord blood units for transplantation. It may also eliminate the need for dual umbilical cord blood transplantation for those without an adequately sized single umbilical cord blood graft. The second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Such a strategy may also address the problem of slow hematopoietic recovery as well as the increased risk of graft failure. Many of these strategies are now being tested in late-phase multi-center clinical trials. If proven cost-effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.",
author = "Horwitz, {Mitchell E.} and Francesco Frassoni",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jcyt.2015.02.004",
language = "English",
volume = "17",
pages = "730--738",
journal = "Cytotherapy",
issn = "1465-3249",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation

AU - Horwitz, Mitchell E.

AU - Frassoni, Francesco

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The outcome of umbilical cord blood transplantation for adult patients with hematologic malignancies now rivals that of matched unrelated donor transplantation. However, relatively low lymphocyte and hematopoietic stem and progenitor cell dose is a source of significant morbidity and mortality. Multiple strategies are now being studied to overcome these limitations. One strategy involves exvivo expansion of the umbilical cord blood unit before transplantation. Exvivo expansion has the potential to increase the number of lymphocytes, committed progenitors and long-term repopulating hematopoietic stem cells. Increasing the numbers of lymphocytes and committed progenitor cells will address the issue of delayed hematopoietic recovery after umbilical cord blood transplantation. Increasing the hematopoietic stem cell content will improve the availability of adequately sized and matched cord blood units for transplantation. It may also eliminate the need for dual umbilical cord blood transplantation for those without an adequately sized single umbilical cord blood graft. The second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Such a strategy may also address the problem of slow hematopoietic recovery as well as the increased risk of graft failure. Many of these strategies are now being tested in late-phase multi-center clinical trials. If proven cost-effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.

AB - The outcome of umbilical cord blood transplantation for adult patients with hematologic malignancies now rivals that of matched unrelated donor transplantation. However, relatively low lymphocyte and hematopoietic stem and progenitor cell dose is a source of significant morbidity and mortality. Multiple strategies are now being studied to overcome these limitations. One strategy involves exvivo expansion of the umbilical cord blood unit before transplantation. Exvivo expansion has the potential to increase the number of lymphocytes, committed progenitors and long-term repopulating hematopoietic stem cells. Increasing the numbers of lymphocytes and committed progenitor cells will address the issue of delayed hematopoietic recovery after umbilical cord blood transplantation. Increasing the hematopoietic stem cell content will improve the availability of adequately sized and matched cord blood units for transplantation. It may also eliminate the need for dual umbilical cord blood transplantation for those without an adequately sized single umbilical cord blood graft. The second strategy involves exposure of the umbilical cord blood graft to compounds aimed at improving homing and engraftment following transplantation. Such a strategy may also address the problem of slow hematopoietic recovery as well as the increased risk of graft failure. Many of these strategies are now being tested in late-phase multi-center clinical trials. If proven cost-effective and efficacious, they may alter the landscape of donor options for allogeneic stem cell transplantation.

UR - http://www.scopus.com/inward/record.url?scp=84929049174&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929049174&partnerID=8YFLogxK

U2 - 10.1016/j.jcyt.2015.02.004

DO - 10.1016/j.jcyt.2015.02.004

M3 - Article

C2 - 25778757

AN - SCOPUS:84929049174

VL - 17

SP - 730

EP - 738

JO - Cytotherapy

JF - Cytotherapy

SN - 1465-3249

IS - 6

ER -